Magnolia Medical has once again filed a lawsuit against Kurin, accusing it of continued infringement of its diagnostic tests for sepsis and other bloodstream infections. This legal action comes in the wake of Kurin’s loss in a 2022 jury trial concerning a different patent. In the suit, Magnolia Medical alleges that Kurin operates using a predatory business model.
While the specifics of the current dispute remain undisclosed, the lawsuit follows a series of intellectual property cases between Magnolia Medical and Kurin. It appears that Magnolia’s earlier victory in court did not deter Kurin from what Magnolia describes as habitual infringement. In light of this ongoing pattern, it seems this will not be the last courtroom encounter between these two diagnostic test manufacturers.
This ongoing litigation could potentially have broad implications, not just for the firms involved, but also for the broader diagnostic test industry. While the suits provide insight into the fiercely competitive nature of diagnostic test development and patent protection, they also underscore the legal challenges that companies face in protecting their intellectual assets in complex technical fields.
For more details on the case, you can read the original Law360 report.